Replies to post #2475 on Actinium Pharmaceuticals Inc (ATNM)

[GD]

Agree 100% with your view of "they are expecting to ask the FDA for an
early termination and proceed to an NDA submission". In my view, "100
percent (31/31) of patients receiving a therapeutic dose of Iomab-B
achieved successful BMT engraftment with only a 6 percent (2/31) TRM rate
compared to the control arm where 18 percent (7/38) achieved engraftment
with a 29 percent (2/7) TRM rate." is a huge success, 84%(31/37) vs 18%
(7/38) chance for CURE intent BMT itself is FDA approvable data, IMO.